| Incyte Corp | 89,31 / -0,51% |
| 日付/時刻 | 26.10. / 16:59 |
| 変化 / 変化(%) | -0,46 / -0,51% |
| Bid | 88,97 / 1 |
| Ask | 89,35 / 1 |
| 始値 | 89,85 |
| 直前終値 | 89,77 |
| 高値 | 90,15 |
| 安値 | 89,01 |
| 出来高 [USD] | 803.948,15 |
| 出来高 [Units] | 14.435 |
| Price fixings | 85 |
| ISIN | US45337C1027 |
| シンボル | INCY |
| 取引所 | Cboe US |
| 種類 | 株式 |
すべての取引所
| 取引所 | 直近 | 出来高 | |
|---|---|---|---|
| NASDAQ | 89,2100 |  |
201.812 |
| IEX | 89,42 | |
16.935 |
| Cboe US | 89,31 | |
14.435 |
| TradeGate | 75,450 | |
185 |
| gettex | 75,630 | |
15 |
| Frankfurt | 74,8800 |  |
0 |
| München | 75,08 | |
0 |
| Düsseldorf | 75,83 | |
0 |
| Berlin | 75,64 | |
0 |
| Lang & Schwa.. | 75,47 |  |
|
| Stuttgart | 75,770 | |
|
| Vienna Globa.. | 75,58 | |
400 |
| London Inter.. | 90,14 | 71 | |
| Mexico | 1.933,00 | |
400 |
ニュース
- BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
21.10.2020 / 12:30 - GlobeNewswire - Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer
06.10.2020 / 13:30 - GlobeNewswire - BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11
06.10.2020 / 12:30 - GlobeNewswire - Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC
05.10.2020 / 13:30 - GlobeNewswire - MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
21.09.2020 / 13:30 - GlobeNewswire